[HTML][HTML] TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing …
Background Globally rifampicin-resistant tuberculosis disease affects around 460,000
people each year. Currently recommended regimens are 9–24 months duration, have poor …
people each year. Currently recommended regimens are 9–24 months duration, have poor …